NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March
NAARDEN, The Netherlands and MIAMI, Feb. 26, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in three upcoming investor conferences:
荷蘭納爾登和邁阿密，2024年2月26日（GLOBE NEWSWIRE）——新阿姆斯特丹製藥公司（納斯達克股票代碼：NAMS 或 “新阿姆斯特丹” 或 “公司”），一家處於後期階段的臨床生物製藥公司，爲有心血管疾病風險且低密度脂蛋白膽固醇（“LDL-C”）升高、現有療法不夠有效或不夠有效的患者開發口服非他汀類藥物容忍度良好，今天宣佈公司管理層將參加三次即將舉行的投資者會議：
- TD Cowen 44th Annual Health Care Conference in Boston, MA on Monday, March 4, 2024. Michael Davidson, Chief Executive Officer, and Ian Somaiya, Chief Financial Officer, will present a corporate overview at 2:10 p.m. ET.
- Leerink Global Biopharma Conference in Miami, FL on Monday, March 11, 2024. Michael Davidson, M.D., Chief Executive Officer, will present a corporate overview at 4:00 p.m. ET.
-
Jefferies Biotech on the Bay Summit in Miami, FL on Tuesday, March 12, 2024. Company management will be available for 1x1 meetings throughout the day.
- TD Cowen第44屆年度醫療保健會議將於2024年3月4日星期一在馬薩諸塞州波士頓舉行。首席執行官邁克爾·戴維森和首席財務官伊恩·索邁亞將在美國東部時間下午 2:10 介紹公司概況。
- Leerink全球生物製藥會議將於2024年3月11日星期一在佛羅里達州邁阿密舉行。首席執行官邁克爾·戴維森醫學博士將在美國東部時間下午 4:00 介紹公司概況。
- 傑富瑞生物科技公司海灣峯會將於2024年3月12日星期二在佛羅里達州邁阿密舉行。公司管理層將全天提供1x1會議。
Live webcasts of both the Cowen and Leerink presentations will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcast, an archived replay will be available on the Company's website.
Cowen和Leerink演講的網絡直播將通過新阿姆斯特丹製藥公司網站ir.newamsterdampharma.com的投資者關係欄目播出。網絡直播結束後，公司網站上將提供存檔重播。
About NewAmsterdam
關於新阿姆斯特丹
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as preferred LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.
NewAmsterdam Pharma（納斯達克股票代碼：NAMS）是一家處於後期階段的生物製藥公司，其使命是改善目前批准的療法不足或耐受性不佳的代謝性疾病患者的患者護理。我們力求滿足對安全、耐受性好、便捷的降低密度脂蛋白療法的巨大需求。在多項3期研究中，NewAmsterdam正在研究obicetrapib，一種口服、低劑量、每日一次的CETP抑制劑，單獨使用或與依澤替米貝作爲固定劑量組合的首選低密度脂蛋白C降低療法，可用作他汀類藥物治療的輔助療法，用於低密度脂蛋白C升高的心血管疾病的患者。
Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com
公司聯繫人
馬修·菲利普
P：1-917-882-7512
matthew.philippe@newamsterdampharma.com
Media Contact
Spectrum Science on behalf of NewAmsterdam
Jen Gordon
P: 1-202-957-7795
jgordon@spectrumscience.com
媒體聯繫人
代表新阿姆斯特丹的頻譜科學
詹·戈登
P：1-202-957-7795
jgordon@spectrumscience.com
Investor Contact
Stern Investor Relations on behalf of NewAmsterdam
Hannah Deresiewicz
P: 1-212-362-1200
hannah.deresiewicz@sternir.com
投資者聯繫人
Stern 投資者關係部代表 NewAmsterdam
漢娜·德雷西維奇
P: 1-212-362-1200
hannah.deresiewicz@sternir.com